Table 2 The efficacy of small molecule antiangiogenic drugs in previously treated thymic carcinomas
From: The efficacy of small molecule anti-angiogenic drugs in previously treated Thymic carcinoma
Total (n = 17) | Apatinib (n = 13) | Anlotinib (n = 4) | P | |
|---|---|---|---|---|
Partial response | 4 (23.5) | 4 (30.8) | 0 (0.0) | |
Stable response | 11 (64.7) | 7 (53.8) | 4 (100.0) | |
Progressive disease | 2 (11.8) | 2 (15.4) | 0 (0.0) | |
Overall response rate, % | 23.5 | 30.8 | 0.0 | 0.519* |
mPFS(95%CI), mo | 7.9 (6.5–9.3) | 7.0 (5.0–9.0) | 8.0 (2.7–13.3) | 1.000** |
mOS(95%CI), mo | 47.0 (35.4–58.6) | 47.0 (43.7–50.2) | 0.076*** |